african
american
man
histori
hypertens
coronari
arteri
diseas
endstag
renal
diseas
hemodialysi
sinc
endstag
heart
failur
secondari
arrhythmogen
right
ventricular
cardiomyopathi
arvc
underw
dual
organ
heartkidney
transplant
may
approxim
two
month
transplant
mycophenol
discontinu
due
episod
pancreat
leukopenia
detect
bk
polyoma
viru
sinc
patient
maintain
tacrolimu
goal
level
ngml
lowdos
prednison
eight
month
transplant
patient
develop
mild
influenza
infect
treat
oseltamivir
day
six
week
later
approxim
ten
month
heartkidney
transplant
patient
repres
cough
product
yellow
sputum
three
day
associ
pleurit
chest
pain
dyspnea
nasal
congest
subject
fever
deni
travel
exposur
known
covid
infect
individu
initi
vital
sign
within
normal
limit
physic
exam
unremark
blood
oxygen
satur
room
air
respiratori
viral
panel
neg
white
blood
cell
count
blood
lactat
normal
absolut
lymphocyt
count
reduc
refer
rang
creactiv
protein
crp
elev
mgl
refer
rang
mgl
initi
chest
xray
reveal
multifoc
pneumonia
fig
patient
start
empir
vancomycin
piperacillintazobactam
azithromycin
baselin
immunosuppress
reduc
prednison
held
tacrolimu
dose
decreas
lower
goal
level
ngml
prophylaxi
opportunist
infect
continu
ganciclovir
atovaquon
oropharyng
swab
nasopharyng
swab
sent
rtpcr
test
patient
admit
airborn
isol
bed
hospit
day
patient
remain
clinic
stabl
room
air
radiograph
worsen
note
fig
rtpcr
test
return
posit
start
lopinavirritonavir
everi
hour
nitazoxanid
everi
hour
day
also
given
one
dose
intraven
immunoglobulin
ivig
tacrolimu
level
follow
daili
given
known
drugdrug
interact
ritonavir
result
decreas
tacrolimu
clearanc
tacrolimu
dose
administ
requir
week
antibacteri
therapi
discontinu
patient
improv
hospit
day
experienc
intermitt
cough
scant
sputum
product
crp
decreas
mgl
discharg
home
selfcar
patient
diseas
exhibit
rel
mild
form
diseas
remain
afebril
maintain
good
oxygen
satur
throughout
hospit
cours
present
similar
report
nonimmunosuppress
patient
similar
present
report
heart
transplant
recipi
china
heart
transplant
recipi
itali
sinc
respiratori
viral
ill
repres
signific
caus
morbid
mortal
age
immunocompromis
transplant
popul
patient
would
like
benefit
earli
screen
aggress
treatment
wherev
possibl
time
proven
target
therapi
avail
regimen
lopinavirritonavir
nitazoxanid
ivig
chosen
patient
histori
dual
organ
transplant
diseas
base
vitro
data
limit
clinic
data
drug
avail
institut
time
patient
diagnosi
recent
random
control
assess
lopinavirritonavir
adult
hospit
sever
report
signific
benefit
howev
emphas
patient
studi
rel
comorbid
may
receiv
treatment
rel
late
diseas
process
unclear
whether
find
extrapol
transplant
popul
import
challeng
consider
use
lopinavirritonavir
transplant
recipi
signific
drugdrug
interact
tacrolimu
limit
data
support
use
antiprotozo
agent
nitazoxanid
antivir
drug
immunomodul
sever
case
seri
report
posit
outcom
transplant
patient
viral
ill
likewis
small
studi
suggest
benefit
use
intraven
immunoglobulin
replac
transplant
recipi
low
level
immunoglobulin
ig
sever
infect
patient
igg
level
lower
limit
normal
prospect
evalu
potenti
therapi
import
tailor
treatment
transplant
popul
pandem
continu
grow
